Parkinson’s/ALS Reviewed by NeuroPerspective

NI Research has released the November/December 2021 issue of NeuroPerspective, which features comprehensive reviews for two major neurodegenerative disorders: Parkinson’s and ALS. These reviews include a consideration of the current thinking around pathophysiology and therapeutic targets, including the protein aggregates considered to be associated with these disorders: Alpha-synuclein, TDP-43, SOD1, and c9orf72.  Neuroinflammation, GBA as a target, LRRK2, the gut-brain microbiome, autophagy, and other mechanisms of current interest are included.

The Parkinson’s review includes 130+ programs, including programs from AbbVie / Mission, AC Immune, Annovis, Bayer, Aspen Neuroscience, BIAL Bio, Biogen, Cantabio,  Caraway, Casma, Denali, Roche/Genentech, Lundbeck, Neuropore,  Prothena/Roche, Sage Therapeutics, UCB Pharma, Vanqua, Axial Biotherapeutics, Yumanity, and Cerevel. The ALS review includes 85+ programs, including Amylyx, Biogen/Ionis, Sanofi/Denali, GSK/Alector, Neuropore, Libra, Locana, Neurimmune, Prilenia, QurAlis, and Verge Genomics

QurAlis is the focus of the Company Spotlight. Sidebars include and overview of the burgeoning roster of CNS portfolio companies (e.g. Neumora, Neurvati, Cambrian, Atai); developments in Alzheimer’s, including results from Cortexyme, AC Immune, and Cassava. Our Psychedelic Update section assesses Pasithea‘s revenue-generation plan as well as developments at Atai/DeMeRx, Field Trip Health, and MindMed. 66 pages.

NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. The November/December review of PD and ALS culminates a two-issue sequence on neurodegeneration, with the September/October 2021 issue having comprehensively covered Alzheimer’s and Huntington’s.

NeuroPerspective is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.  A one-year (1-5 user) subscription to NeuroPerspective is $2900. A 6-10 user subscription is $4950. Other customized userbase and  startup pricing options are available. The Parkinson’s/ALS  review issue of NeuroPerspective is available as a single-issue purchase for $700.